Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00266812 | Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED) | terminated | Phase 2 | 35 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 8, 2017 | clinicaltrials |
| NCT00423150 | Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED) | terminated | Phase 2 | 86 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 8, 2017 |
| clinicaltrials |
| NCT00632203 | Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146) | terminated | Phase 2 | 53 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00592007 | Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer | terminated | Phase 2 | 7 | Lyudmila Bazhenova, M.D.OTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT00034697 | Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143) | terminated | Phase 2 | 24 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 23, 2017 | clinicaltrials |
| NCT00801801 | Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC | terminated | Phase 2 | 5 | Francisco Robert,MDOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT02276560 | Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC(LCCC1407) | terminated | Phase 2 | 1 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 11, 2017 | clinicaltrials |
| NCT01719861 | Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors | terminated | Phase 2 | 6 | Joel NealOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT00126451 | A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED) | terminated | Phase 2 | 16 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 10, 2017 | clinicaltrials |
| NCT02087241 | Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer | terminated | Phase 2 | 22 | AstraZenecaINDUSTRY | 1 | Mar 29, 2017 | clinicaltrials |
| NCT00351039 | Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 8 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 23, 2017 | clinicaltrials |
| NCT01319669 | Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy | terminated | Phase 2 / Phase 3 | 11 | Chinese Society of Lung CancerOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT02095782 | Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation(INNOVATE) | terminated | Phase 2 | 10 | Guangdong Association of Clinical TrialsOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00073008 | A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer | terminated | Phase 2 | 131 | GlaxoSmithKlineINDUSTRY | 2 | Feb 28, 2017 | clinicaltrials |
| NCT01383148 | Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer(TIME) | terminated | Phase 2 / Phase 3 | 222 | TransgeneINDUSTRY | 10 | Jan 5, 2017 | clinicaltrials |
| NCT00921310 | Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 12 | Washington University School of MedicineOTHER | 1 | Dec 13, 2016 | clinicaltrials |
| NCT00352690 | A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer | terminated | Phase 2 | 10 | Washington University School of MedicineOTHER | 1 | Dec 12, 2016 | clinicaltrials |
| NCT00642824 | A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. | terminated | Phase 2 | 3 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01997775 | Metformin in Stage IV Lung Adenocarcinoma | terminated | Phase 2 | 13 | National Cheng-Kung University HospitalOTHER | 1 | Sep 30, 2016 | clinicaltrials |
| NCT00404703 | A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer | terminated | Phase 2 | 37 | Hoffmann-La RocheINDUSTRY | 10 | Aug 24, 2016 | clinicaltrials |
| NCT00417248 | Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 8 | Nasser Hanna, M.D.OTHER | 1 | Jul 25, 2016 | clinicaltrials |
| NCT00787267 | Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC(TOP0801) | terminated | Phase 2 | 37 | Duke UniversityOTHER | 1 | Jun 30, 2016 | clinicaltrials |
| NCT02087176 | A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer | terminated | Phase 2 | 48 | AstraZenecaINDUSTRY | 1 | Jun 14, 2016 | clinicaltrials |
| NCT02351505 | Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer | terminated | Phase 2 | 1 | Erin BertinoOTHER | 1 | May 16, 2016 | clinicaltrials |
| NCT00732303 | Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer | terminated | Phase 2 | 8 | Hoosier Cancer Research NetworkOTHER | 1 | Apr 27, 2016 | clinicaltrials |
| NCT00766246 | Phase II Avastin Trial for Stage IIIB/IV NSCLC | terminated | Phase 2 | 125 | PharmatechINDUSTRY | 0 | Apr 19, 2016 | clinicaltrials |
| NCT01819428 | NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma | terminated | Phase 2 | 22 | National OncoVentureOTHER | 1 | Mar 1, 2016 | clinicaltrials |
| NCT00299390 | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer | terminated | Phase 2 | 10 | BayerINDUSTRY | 0 | Dec 31, 2015 | clinicaltrials |
| NCT01193868 | RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Nov 18, 2015 | clinicaltrials |
| NCT01159327 | Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy | terminated | Phase 2 | 13 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 11, 2015 | clinicaltrials |
| NCT01577212 | Individualized Dose Prescription in Advanced Stage Lung Cancer Patients Using Modern (Chemo)Radiotherapy(IDEAL-VMAT) | terminated | Phase 2 | 6 | Radboud University Medical CenterOTHER | 1 | Nov 9, 2015 | clinicaltrials |
| NCT01348126 | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer(GALAXY) | terminated | Phase 2 / Phase 3 | 385 | Synta Pharmaceuticals Corp.INDUSTRY | 13 | Nov 5, 2015 | clinicaltrials |
| NCT00850577 | Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer | terminated | Phase 2 | 255 | Bristol-Myers SquibbINDUSTRY | 8 | Oct 12, 2015 | clinicaltrials |
| NCT00923949 | Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT00749567 | Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer | terminated | Phase 2 | 13 | Hellenic Oncology Research GroupOTHER | 1 | Sep 28, 2015 | clinicaltrials |
| NCT02179567 | Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC | terminated | Phase 2 | 26 | Hellenic Oncology Research GroupOTHER | 1 | Sep 28, 2015 | clinicaltrials |
| NCT01057212 | Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 6 | Providence Health & ServicesOTHER | 1 | Sep 7, 2015 | clinicaltrials |
| NCT00983047 | Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer | terminated | Phase 2 | 30 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | Aug 27, 2015 | clinicaltrials |
| NCT00391586 | Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung | terminated | Phase 2 | 45 | New Mexico Cancer Research AllianceOTHER | 1 | Aug 17, 2015 | clinicaltrials |
| NCT00290550 | A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006) | terminated | Phase 2 | 22 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 27, 2015 | clinicaltrials |
| NCT01222572 | Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 1 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT01421316 | Hair-sparing Whole Brain Radiotherapy | terminated | Phase 2 | 29 | University Hospital, GhentOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00431613 | Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without Consolidation Chemotherapy, in IIIA/IIIB Non Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 38 | Hellenic Oncology Research GroupOTHER | 1 | May 29, 2015 | clinicaltrials |
| NCT01038752 | Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer | terminated | Phase 2 | 14 | Optimum Therapeutics, LLCINDUSTRY | 1 | May 21, 2015 | clinicaltrials |
| NCT00238615 | Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC | terminated | Phase 2 | 13 | Stanford UniversityOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT00974662 | Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer | terminated | Phase 2 | 3 | Steba Biotech S.A.OTHER | 1 | Apr 28, 2015 | clinicaltrials |
| NCT00940875 | A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 54 | Hoffmann-La RocheINDUSTRY | 1 | Apr 2, 2015 | clinicaltrials |
| NCT00251589 | A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025) | terminated | Phase 1 / Phase 2 | 23 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 6, 2015 | clinicaltrials |
| NCT00564876 | Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer(TOP0706) | terminated | Phase 2 | 2 | Duke UniversityOTHER | 1 | Feb 23, 2015 | clinicaltrials |
| NCT00661011 | Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy | terminated | Phase 2 | 75 | European Lung Cancer Working PartyOTHER | 3 | Feb 12, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2017source: clinicaltrials